Replies to post #41743 on SiNtx Technologies Inc (SINT)

[PioneerPhoenix73]

Oh my! Buckle up, shareholders! It's almost time for the annual meeting filing, that thrilling document that keeps us all on the edge of our seats. Will it contain juicy details about... who knows, really? But hey, maybe they'll throw us a bone and include a vote on a new employee share plan! After all, the last one mysteriously vanished right before that, uh, "generous" reverse split. Just a coincidence, I'm sure. Like a magician pulling a rabbit out of a hat, then stuffing it back in right before you get a good look.

Speaking of magic tricks, isn't it fascinating how that employee share plan vote conveniently failed and then poof the biggest reverse split ever appeared? Maybe it was all just a misunderstanding, a case of misplaced paperwork. But hey, at least they have a history of these votes, right? Every few years, like clockwork, they dangle a shiny new share plan in front of us, just to yank it away at the last minute.

But fret not, my fellow investors! We have mountains of research (emphasis on research, because apparently some people need help connecting the dots) to keep us occupied. Did someone say "Sintx connections?" We've got a whole network here, folks! Zimmer Biomet, their old pal for 20 years ( practically childhood sweethearts!), Morgan Ceramics with their fancy aerospace products (who needs boring medical stuff, anyway?), and don't forget ZimVie and Solventum, because why not throw everything in the mix? And to top it all off, Cardinal Health for good measure, because who doesn't need some PPE with their cutting-edge bioceramic armor plates?

The possibilities are truly endless! Just think, with this kind of diversification, Sintx could corner the market on everything from condoms to catheters. A one-stop shop for all your, uh, delicate needs.

So let's all raise a glass (filled with a magical growth elixir, perhaps?) to the upcoming annual meeting filing. May it be filled with more questions than answers, and keep the speculation machine churning at full speed!

[boston745]

In Post #17 on my board, i began to describe things i was seeing that suggested that things going on here were not as they seemed to me. That maybe these are not hostile parties attacking SINT but related parties attacking SINT. It began with someone trying to get me to sell days before Sintx announced the offering price in Feb 2023 as described in that post. How did this account know about the forthcoming offering? Then there were several posts summer of 2023 indicating that SIntx would follow the same path as Sonny's friend over at ConforMIS as Confor went private way undervalued for reasons i honestly havent looked into. However there have been two main things that have really had me concerned.

The first one is that despite talking to me about range of subjects and companies, these social media accounts avoid talking about 1 specific company. That company is NP Aerospace, a company i have recently showed to be a likely partner based on both companies working on female specific body armor at the same time and other ties. It was only after claiming several times that these accounts cannot talk about NP Aerospace that they would even mention that company, albeit barely & briefly. If they cannot truly discuss this company it means they are somehow bound not to or fear they might incriminate themselves/ reveal truth if they did. If they do not want to lie or fear revealing truth, that means they are aware of more of whats going on and thus represent one of the parties involved. This while the bulk of their posts are skewed very negatively against Sintx. Meaning if they are aware of whats going on, they are purposefully trying to help devalue SINT for some endgame.
Related to this, back in August i began to increase my claims about Sintx & NP Aerospace's relationship. Shortly afterwards, Sintx announced the closing of its Salt Lake city armor facility. While the timing is a little suspect and interesting, not to mentioned rushed as they made this decision the day before the Q2 filing, it fits with their cost cutting measures. However there are two aspects to this that suggests that the company and a previous named poster, do not want me to discuss Sintx and NP Aerospace. Firstly the company did not indicate what direction it was going in regards to manufacturing armor since it was closing its only disclosed armor facility. This suggests that its plans in regards to this subject are undisclosable material information at that time. Then there was a post by Atlanta1 with the paragraph about Sintx shutting down its SLC armor facility that was posted about 30mins after the acceptance of Sintx 10Q filing. This despite the quote being on page 18 of the filing...almost as if he knew it was there. The mocking tone to his post suggests he wanted me to believe that Sintx was exiting the armor market , which he later tried to say was true, and that would mean Sintx was not working with NP Aerospace. This despite no indication from the company that it had any intention to exit the armor market; its still taking orders on its website connected to armor. This was implied with his roflmfao post # 41436 linked below in response to my post calling out JoeV2 cop-out in his post claiming he doesnt care enough to talk about Sintx-NP Aerospace. As it turns out, Sintx has a second armor manufacturing facility in Maryland at one of its TA&T buildings providing an alternative manufacturing facility if they so choose. A facility that is closer to the heart of US defense, making it more strategic for a company like NP Aerospace than Salt Lake. Again its odd they didnt just specify this as they already disclosed they moved their quality management process over to TA&T which would allow it to manufacture for aerospace/defense & medical industries.

The next concerning thing was in April of 2024 when specific accounts, again this is covered in post 17 linked below, tried to get me to post on Cafepharma by posting about it here while also trying to goad me there. When they did this i began to suspect that they were trying to repeat their previous methods back in 2018. Namely to get me to post about Sintx and Zimmer Biomet to potentially distract from other possible strategic maneuvers. If this was in fact the game they were playing, that means what was to be announced a couple months later, did not have to do with Zimmer Biomet and they already knew it. Another reason for them to want me to talk about Sintx and Zimmer Biomet is so they can try to reinforce that Im trying to scam people and there is nothing going on between Sintx and Zimmer Biomet despite close to 20 years of them working together.
Yes i do think Zimmer Biomet will come out from behind the curtain one day, just not yet based on what im seeing.
That brings me to another point, they do not like me talking about Amylin Pharma and Eli Lilly. Why would that be? Amylin and Sintx share a lot of parallels and what occurred with Amylin maybe similar to what will happen with Sintx.

Both Amylin and Sintx were founded by people connected to the companies they eventually partnered with. Sintx was co-founded by Dr Hofmann, MD who was a surgeon designer for Centerpulse/Zimmer. Amylin founded by Howard Greene Jr who just sold a company to Eli the year prior. Like Amylin, Sintx had two board members with ties to Zimmer in Dr Link, PHD who was Chairman from 2003-2014, & Dr Sonny Bal, MD. Dr Link was CEO of Centerpulse for its deal with Zimmer. Dr Bal was on Zimmer's scientific panel doing work for them since 2002 up until at least 2014 according to Dr Bal's 2014 resume. Former Eli Lilly executives were on Amylin's board: Joseph Cook who became CEO & Chairman like Sonny Bal, and Gringer Graham who became CEO after Cook stepped down as CEO but remained Chairman.
Anyways, Eli Lilly eventually partnered with Amylin just like Biomet/Zimmer Biomet partnered with Sintx; difference here is theres been no official disclosure of Sintx and Biomet/Zimmer Biomet's partnership only inferred partnerships through joint IP testing. However Eli Lilly did not acquire Amylin in the end, Bristol Myers does. Ok, that happens right? Well, whats particularly interesting is Eli doesnt acquire its partner Amylin in 2008 but instead acquires Bristol Myers partner ImClone with Carl Icahn being the one that helped broker that deal. Then Mr Icahn removes Eli Lilly board members on Amylin and oversees the sell of Amylin to Bristol Myers in 2012. What that suggests to me is a deal was made behind the scenes at some point for Eli and Bristol Myers to acquire each others partners, drug swap, and Carl Icahn worked as the public face of the deal. There are more details here to support this like Eli Lilly no longer needing Amylins drugs because of ImClones drugs but also in Amylins board not wanting to sell yet in 2009 because it believed that shareholders would not get sufficient value at that time.

This has me wondering, do people not like me posting about Amylin/Eli Lilly because a similar type of deal was orchestrated years ago? It would not be the same i'll acquire yours and you acquire mine type scenario. If Sintx and NP Aerospace merge in any way then its possible an agreement was made between Zimmer Biomet and Morgan Ceramics behind the scenes which led Morgan to divest NP and Sintx to divest Amedica at the same time. In parallel to that Zimmer Biomet was getting ready to divest Spine/Dental IP like Sintx did. I see this going a couple different directions. Zimmer Biomet could acquire this newly merged company and become more like J&J or it could simply acquire IP from the merged company injecting NP with alot of capital to further fund its expansion within the defense markets. Zimmer Biomet needs to diversify itself as pandemics hurt its business more than other major ortho companies. I feel Sintx is sufficient in helping Zimmer Biomet diversify its portfolio given all the significant markets Sintx IP can be used in. However i do not know Zimmer Biomets longterm plans.

I am getting ahead of myself here as I need to cover a major variable thats been at play since 2015. Anson and its family of hedge funds. Whats particularly interesting is this family of funds were shorting/distorting/participating in offerings from 2015-2018. Then pickup at an accelerated pace in 2023 although theres signs they were working the price in 2022 as well. The period of 2019-2022 when this group of funds was not obvious in their participation in offerings, Sintx was gearing up to supply the defense markets getting AS9100D certified and acquiring armor assets/TA&T facility. Interestingly as soon as the TA&T deal was done Sintx stockprice began its rapid descent. I'll go more into all this in a followup post.

10-Q accepted at : Accepted 2024-08-13 16:32:31
Post # 41436 (Posted Tuesday, August 13, 2024 5:04:22 PM)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174914418

Post #17
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175290356

========================================

Here is a collection of my research going over multiple subjects pertaining to Sintx connections with Zimmer Biomet, Solventum, Morgan Ceramics, & NP Aerospace. Includes other reseearch topics as well.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175270333

========================================

We already know Sintx and Morgan were working together. If there is going to be some sort of NP/Sintx merger, that just solidifies it. We also know Zimmer Biomet and Sintx have had a long standing relationship (going on 20 years) so as long as Sintx components for Arthroplasty are any good, Zimmer Biomet will come out from behind the curtain. With ZB comes ZimVie and I believe Solventum because of Bryan Hanson. Leaving only Cardinal Health which is suggested by Sintx hiring of Joseph Palomo who joined Sintx from Cardinal Health R&D division.

Morgan Ceramics = Aerospace products
Zimmer Biomet = Arthroplasty oriented products
ZimVie = Dental?
Solventum = Wound Care, Catheters, & possibly Cancer treatment products.
Cardinal Health = PPE & Medical protection apparel.
NP Aerospace = Armor plates & other possible products connected to TA&T.

========================================

Markets Si3n4/Sintx Ceramics can be used in (not comprehensive)

Otho Market = $64 billion
Personal Protective Equipment market = $79.53 billion
Global Catheter market = $55bn
Antibacterial market = $44.5bn
Wound Care market = $22.25bn
Biosensors Market = $28.9bn
Condom Market = $11.6bn
Dental Implant market = $4.99bn
Armor Materials Market = $13.59bn

Total = $324.26bn

Sources:
https://web.archive.org/web/2024040...ogger.blogspot.com/2011/05/whos-next.html?m=1
https://orthospinenews.com/2021/01/...y-2025-as-acquisitions-surge-says-globaldata/
https://www.grandviewresearch.com/industry-analysis/personal-protective-equipment-ppe-market
https://www.grandviewresearch.com/industry-analysis/catheters-market-analysis
https://www.grandviewresearch.com/industry-analysis/wound-care-market
https://www.grandviewresearch.com/industry-analysis/biosensors-market
https://www.grandviewresearch.com/industry-analysis/condom-market
https://www.mordorintelligence.com/industry-reports/armor-materials-market
https://www.grandviewresearch.com/industry-analysis/dental-implants-market

[boston745]

About time for the annual meeting filing. Be curious what will be on it? Should include a new vote on employee share plan since last years plan was voted down conveniently before a massive RS.

They just filed the annual meeting and it includes the new employee share plan expansion of shares. What direction that goes will give us an idea if there will be a RS next year into 2026 as some accounts like to invoke. If it fails theres a high chance of a RS. If it passes, which I expect, then RS is unlikely. I do not like how this is going down but you'll hear no argument from me that management & its employees deserves shares for the value they have created; even though that value is not currently reflected by the stock price. The sheer expansion of scope of IP is grounds enough in my opinion. Looks like the employee plan will give employees up to 20% of current outstanding shares when factoring in these new ones increasing OS to 1.6m if fully distributed because of a change in control.

Second filing today was Lind Partners indicating that they have 35,750 series E & 35,750 Series F warrants. The exercise price of those warrants should be 50 dollars. The Series F warrants expire August 2025. If they exercised those fully thats $3.6m unless they do some sort of cashless exercise.

The Class E and Class F Warrants were immediately exercisable at a price of $50.00 per share.

Lind is part of Ansons family of hedge funds that have been shorting and distorting on and off here since 2015 and played the pump in 2020 via Sabby fund. Here is the list of funds with all the funds in red being funds that have participated in Sintx offerings through the years.

Plaintiff further asserts that many of the potential investors that it contacted on behalf of Defendant operate as a family of hedge funds, all managed by the same investment advisor.

List of potential investors the Plaintiff was referencing. All the funds that seem to be connected are in red.

List named the following:
Anson Funds Management LP and its affiliates
Ayrton Capital, Altos Opportunity Fund and their
affiliates
Crede Capital Group, Acquitas Capital and its affiliates
CVI Investment, Heights Management, SIG and their
affiliates
Connective Capital and its affiliates
Empery Asset Management and its affiliates
Intracoastal Capital LP and its affiliates
Hudson Bay Capital Management and its affiliates
Ionic Venture LLC and its affiliates
Lind Partners and its affiliates
Li Capital Global Opportunities Master Fund and their
affiliates
Sabby Management LLC and its affiliates

Quote Sources 2&3
https://www.sec.gov/ix?doc=/Archives/edgar/data/1269026/000149315224044728/form10-q.htm pg 9
https://images.law.com/contrib/content/uploads/documents/404/140289/51-2023-08-31-043-Order-Denying-SJMotion.pdf

========================================

Here is a collection of my research going over multiple subjects including Sintx connections with Zimmer Biomet, Solventum, Morgan Ceramics, & NP Aerospace. Includes other research topics as well.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175357996

========================================

We already know Sintx and Morgan were working together. If there is going to be some sort of NP/Sintx merger, that just solidifies it. We also know Zimmer Biomet and Sintx have had a long standing relationship (going on 20 years) so as long as Sintx components for Arthroplasty are any good, Zimmer Biomet will come out from behind the curtain. With ZB comes ZimVie and I believe Solventum because of Bryan Hanson. Leaving only Cardinal Health which is suggested by Sintx hiring of Joseph Palomo who joined Sintx from Cardinal Health R&D division.

Morgan Ceramics = Aerospace products
Zimmer Biomet = Arthroplasty oriented products
ZimVie = Dental?
Solventum = Wound Care, Catheters, & possibly Cancer treatment products.
Cardinal Health = PPE & Medical protection apparel.
NP Aerospace = Armor plates & other possible products connected to TA&T.

========================================

Markets Si3n4/Sintx Ceramics can be used in (not comprehensive)

Otho Market = $64 billion
Personal Protective Equipment market = $79.53 billion
Global Catheter market = $55bn
Antibacterial market = $44.5bn
Wound Care market = $22.25bn
Biosensors Market = $28.9bn
Condom Market = $11.6bn
Dental Implant market = $4.99bn
Armor Materials Market = $13.59bn

Total = $324.26bn

Sources:
https://web.archive.org/web/2024040...ogger.blogspot.com/2011/05/whos-next.html?m=1
https://orthospinenews.com/2021/01/...y-2025-as-acquisitions-surge-says-globaldata/
https://www.grandviewresearch.com/industry-analysis/personal-protective-equipment-ppe-market
https://www.grandviewresearch.com/industry-analysis/catheters-market-analysis
https://www.grandviewresearch.com/industry-analysis/wound-care-market
https://www.grandviewresearch.com/industry-analysis/biosensors-market
https://www.grandviewresearch.com/industry-analysis/condom-market
https://www.mordorintelligence.com/industry-reports/armor-materials-market
https://www.grandviewresearch.com/industry-analysis/dental-implants-market